Efficacy of intravenous propranolol for life‐threatening diffuse neonatal hemangiomatosis
Efficacy of intravenous propranolol for life‐threatening diffuse neonatal hemangiomatosis
复制标题
静脉注射普萘洛尔治疗危及生命的弥漫性新生儿血管瘤的疗效
DOI：
10.1111/pde.15028
复制
发表时间：
2022
影响因子：
1.5
通讯作者：
Uchiyama Hiroki
中科院分区：
文献类型：
--
作者：
Ishikawa Takamichi;Seki Keigo;Uchiyama Hiroki
口服普奈洛尔被推荐作为需要系统治疗的婴儿血管瘤的一线药物。危及生命的并发症，如呼吸道梗阻性婴幼儿血管瘤或婴幼儿肝血管瘤合并高输出量充血性心力衰竭，是考虑早期治疗的主要指征。我们报告一例新生儿弥漫性血管瘤病，包括声门下血管瘤引起的呼吸道阻塞，多发性肝血管瘤合并门肝静脉分流引起的心力衰竭，以及持续胃肠道出血引起的严重贫血，其中普奈洛尔静脉注射治疗成功。
Oral propranolol is recommended as the first‐line agent for infantile hemangioma requiring systemic treatment. Life‐threatening complications such as obstructive infantile hemangioma of the airway or infantile hepatic hemangioma associated with high‐output congestive heart failure are major indications for the consideration of early treatment. We present the case of an infant with life‐threatening diffuse neonatal hemangiomatosis, including airway obstruction due to subglottic hemangioma, heart failure due to multiple hepatic hemangiomas with portohepatic venous shunts, and severe anemia due to continuous gastrointestinal bleeding, in which treatment with intravenous propranolol proved successful.
普萘洛尔治疗孤立性眼眶婴儿血管瘤。
DOI：
--
发表时间：
2010
期刊：
A M A Archives of Ophthalmology
影响因子：
--
作者：
A. Fay;J. Nguyen;F. Jakobiec;Lutz Meyer;M. Waner
通讯作者：
M. Waner